Hepatitis C News and Research

Latest Hepatitis C News and Research

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®.

26 Jul 2014

Viewpoints: Ryan's 'thoughtful blueprint' to end poverty; GOP challenges after health law ruling

The Republican chairman of the House Budget Committee today released a thoughtful blueprint for overhauling $800 billion worth of U.S. anti-poverty programs.

26 Jul 2014

Trials show immunizations are effective in adults

As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert.

26 Jul 2014

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities.

26 Jul 2014

MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira, Inc. is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C.

26 Jul 2014

Expensive hepatitis drug challenges Medicaid programs' funding

State officials are nervous about how to afford the new medicine, which can run $84,000 for treatment. Also in Medicaid news, federal data show children using emergency room treatment at night or weekends are often on Medicaid.

26 Jul 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014

First Edition: July 25, 2014

Today's headlines include reports that the Obama administration is moving ahead in preparations for the health law's employer mandate.

25 Jul 2014

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs.

25 Jul 2014

First Edition: July 24, 2014

Today's headlines include more analysis of this week's conflicting appeals courts' decisions regarding a key part of the health law.

24 Jul 2014

New momentum: WHO welcomes progress in tackling viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world's most serious diseases. Viral hepatitis - a group of infectious diseases known as hepatitis A, B, C, D, and E - affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year.

23 Jul 2014

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’

23 Jul 2014

Drug industry news: FDA again offers warning about a Dallas compounding pharmacy; more on Sovaldi

For the third time in 15 months, the FDA is warning health care providers and consumers not to use drugs that were made by a Dallas compounder because the medicines may be contaminated. And the ongoing struggle between the agency and NuVision Pharmacy underscores the difficulties that beset the pharmaceutical supply chain despite a recently passed law designed to bolster safety (Silverman, 7/21).

23 Jul 2014

Cost of Sovaldi and other specialty drugs worries states, pharmaceutical executives

News outlets continue to examine how Solvadi - usually an expensive cure for hepatitis-C - might affect budgets.

22 Jul 2014

First Edition: July, 21, 2014

Today's headlines include a story about an effort by regulators to widen insurer networks, as well as a range of other health policy developments.

21 Jul 2014

State highlights: Concerns continue about Coakley-partners antitrust settlement; Maine's Lepage announces extra $13.1 million for nursing homes

Criticism of Attorney General Martha Coakley's antitrust pact with the state's largest health care system mounted Thursday as a watchdog panel warned a judge the proposed deal might not meet its goal of holding down medical expenses.

21 Jul 2014

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.

21 Jul 2014

UT Southwestern researcher named recipient of ASBMB Merck Award for research on molecular biology

Dr. Zhijian "James" Chen, Professor of Molecular Biology and a Howard Hughes Medical Institute investigator at UT Southwestern Medical Center, has been named the 2015 recipient of the American Society for Biochemistry and Molecular Biology Merck Award, which recognizes outstanding contributions to research in biochemistry and molecular biology.

18 Jul 2014

First Edition: July 18, 2014

Today's headlines include reports from the marketplace, including UnitedHealthcare's move toward the health law's insurance marketplaces and the latest on the Securities and Exchange Commission investigation into insider trading related to a health policy change.

18 Jul 2014

Viewpoints: GOP's 'cynical' lawsuit against Obama; debt crisis is not over

There's not much that Republicans like about the 2010 Affordable Care Act, but one thing they particularly dislike is the requirement that employers with 50 or more full-time workers provide comprehensive health insurance.

18 Jul 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

Viewpoints: Ryan's 'thoughtful blueprint' to end poverty; GOP challenges after health law ruling

Trials show immunizations are effective in adults

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

MedMira adds three new rapid vertical flow tests to Multiplo product line

Expensive hepatitis drug challenges Medicaid programs' funding

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

First Edition: July 25, 2014

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

First Edition: July 24, 2014

New momentum: WHO welcomes progress in tackling viral hepatitis

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Drug industry news: FDA again offers warning about a Dallas compounding pharmacy; more on Sovaldi

Cost of Sovaldi and other specialty drugs worries states, pharmaceutical executives

First Edition: July, 21, 2014

State highlights: Concerns continue about Coakley-partners antitrust settlement; Maine's Lepage announces extra $13.1 million for nursing homes

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

UT Southwestern researcher named recipient of ASBMB Merck Award for research on molecular biology

First Edition: July 18, 2014

Viewpoints: GOP's 'cynical' lawsuit against Obama; debt crisis is not over

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in